Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...
There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...
Now, following up on that success, a large Chinese collaboration has followed up with a description of an improved gene ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
A treatment used a gene-editing tool to turn off a gene that prevents LDL cholesterol and triglycerides from being cleared ...
The U.S. Food and Drug Administration (FDA) on Friday announced that it has approved Casgevy, the first CRISPR gene-editing therapy for sickle cell disease, paving the way for thousands of patients in ...
Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.
The ACC has published a scientific statement regarding the use of gene editing therapy for cardiovascular disease.
Scientists at Rothamsted Research have successfully developed wheat with dramatically reduced levels of asparagine, without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results